Abstract
Multiplexed diagnostics are the wild west of medicine. Technology is
established, regulation is limited and the number of new biomarkers exploding.
First-movers are grabbing biomarker territories, combining independent
measurements for efficiency and mining molecules for multivariate panels. All
the while demand is high for improving diagnoses and predicting responses to
treatment. The challenges, however, are uncertain reimbursement, unclear
business models and ever-intensifying competition. On balance, though, the
market is prosperous and is estimated to be more than $1.5 billion in 2007 and
is projected to grow to more than $6 billion by 2013.
Successful navigation of this difficult terrain requires a detailed
understanding of the market. Multiplexed Diagnostics 2008 explains the unmet
needs, trends, regulations, competition, technologies and business strategies.
The 260-page report includes a survey of more than 200 respondents, a detailed
database of more than 135 commercial multiplexed diagnostics and a
quantitative market model. In addition, the report comes with one hour of
consulting (in the form of a conference call) with the lead author, Steven
Bodovitz, Principal of BioPerspectives.
| 
View Cart
